ACELYRIN, INC. to Join Upcoming Investor Conferences

LOS ANGELES, Aug. 22, 2024 -- ACELYRIN, INC. (Nasdaq: SLRN), a biopharmaceutical company in the late stages of clinical development, is dedicated to fast-tracking the creation and distribution of groundbreaking treatments in the field of immunology. ACELYRIN announced that its management team will be actively participating in fireside chats and one-on-one meetings at a series of upcoming investor conferences.

The company’s representatives are scheduled to attend the following events:

1. Wells Fargo Healthcare Conference 2024:
- Date: Thursday, September 5, 2024
- Location: Boston, MA
- Fireside chat: 1:30 PM - 2:05 PM ET

2. Morgan Stanley 22nd Annual Global Healthcare Conference:
- Date: Friday, September 6, 2024
- Location: New York, NY
- Fireside chat: 11:30 AM - 12:05 PM ET

3. H.C. Wainwright 26th Annual Global Investment Conference:
- Date: Monday, September 9, 2024
- Location: New York, NY
- Fireside chat: 2:00 PM - 2:30 PM ET

ACELYRIN will offer live webcasts of these discussions on its website under the Events & Presentations section. Additionally, replays of each session will be accessible on the company’s website for 30 days after the events.

About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is devoted to providing patients with transformative new treatments by identifying, acquiring, and expediting the development and commercialization of innovative medicines. The company's lead program, lonigutamab, is a subcutaneously administered monoclonal antibody targeting IGF-1R, which is being explored as a treatment for thyroid eye disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!